Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with apraclonidine 0.5%

R L Gross1, A Pinyero, S Orengo-Nania

  • 1Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA.

Journal of Glaucoma
|November 5, 1997
PubMed
Summary

Apraclonidine 0.5% effectively lowers intraocular pressure (IOP) in chronic glaucoma patients for up to 24 months, though some may experience ineffectiveness or allergic reactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validity of code based algorithms to identify primary open angle glaucoma (POAG) in Veterans Affairs (VA) administrative databases.

Ophthalmic epidemiology·2017
Same author

A double-masked, placebo-controlled evaluation of timolol in a gel vehicle.

Journal of glaucoma·2009
Same author

5-Fluorouracil tissue levels after direct application on whole human eyes.

Journal of glaucoma·2009
Same author

Intraoperative 5-Fluorouracil administration in trabeculectomy.

Journal of glaucoma·2009
Same author

Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.

The British journal of ophthalmology·2008
Same author

"Heavy electron" photoelectron spectroscopy: rotationally resolved ion pair imaging of CH3+.

Science (New York, N.Y.)·2001

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma is a leading cause of irreversible blindness worldwide.
  • Effective long-term intraocular pressure (IOP) management is crucial for preventing glaucomatous optic nerve damage.

Purpose of the Study:

  • To evaluate the long-term clinical experience with apraclonidine 0.5% in managing chronic glaucoma.
  • To assess IOP reduction, drug ineffectiveness, allergic reactions, and additivity with other anti-glaucoma medications.

Main Methods:

  • Retrospective review of 174 consecutive patients treated with apraclonidine 0.5%.
  • Exclusion of patients with prior apraclonidine use or multiple simultaneous medication changes.
  • Follow-up up to 24 months to evaluate IOP reduction, ineffectiveness, and allergic reactions.

Main Results:

  • Overall IOP reduction ranged from 19% to 26%.
  • In responders, IOP reduction was 22.5% to 29%.
  • 21% of patients experienced ineffectiveness, and a similar percentage developed allergic reactions.

Conclusions:

  • Apraclonidine 0.5% demonstrates efficacy in reducing IOP for chronic glaucoma.
  • The medication provides sustained IOP control for up to 24 months.
  • Clinicians should monitor for potential ineffectiveness and allergic reactions.

Related Experiment Videos